A rush to market in the US and a trickle in Europe
This article was originally published in Clinica
The defining development for medtech companies in 1996 was the rush of US development-stage businesses to the stock market during the first half of the year. This was followed by what must have been considerable disappointment for many early investors during the second half of the year when many newly-floated companies performed badly. Of the 46 initial public offerings in the US, the share price of 10 companies halved by December. Only 18 managed an increase, but three more than doubled in value between their flotation and December.